Linked Life Data

9182112

Source:http://linkedlifedata.com/resource/pubmed/id/9182112

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
1997-6-10
pubmed:abstractText
Cefuroxime axetil has been evaluated previously in the treatment of lower respiratory tract infections, but not specifically in the treatment of community-acquired pneumonia. In a multicentre, investigator-blinded clinical trial, 162 patients with community-acquired pneumonia were randomly assigned to receive orally either cefuroxime axetil 500 mg bid (n = 84) or amoxycillin/clavulanate 500 mg/125 mg tid (n = 78) for 10 days. Organisms were isolated from the pretreatment sputum specimens of 97 of 162 (60%) patients, the commonest isolates being Streptococcus pneumoniae (38%) and Haemophilus influenzae (18%). A satisfactory clinical outcome (cure or improvement) was achieved in 100% (55 of 55) and 96% (49 of 51) of the clinically evaluable patients treated with cefuroxime axetil or amoxycillin/clavulanate, respectively (P = 0.23). With respect to eradication of bacterial pathogens, a satisfactory outcome (cure, presumed cure or cure with colonization) was obtained in 94% (32 of 34) and 93% (37 of 40) of bacteriologically evaluable patients treated with cefuroxime axetil or amoxycillin/clavulanate, respectively (P = 1.00). Both treatment regimens used in this study were well tolerated. The most common drug-related adverse experiences were gastrointestinal events, reported by 8% and 4%, respectively, of the patients in the amoxycillin/clavulanate and cefuroxime axetil groups, a difference which was not statistically significant (P = 0.32). These results indicate that cefuroxime axetil twice a day is as effective as amoxycillin/clavulanate three times a day in the treatment of outpatients with mild to moderate community-acquired pneumonia.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
0305-7453
pubmed:author
pubmed:issnType
Print
pubmed:volume
37
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
555-64
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:9182112-Administration, Oral, pubmed-meshheading:9182112-Adolescent, pubmed-meshheading:9182112-Adult, pubmed-meshheading:9182112-Aged, pubmed-meshheading:9182112-Aged, 80 and over, pubmed-meshheading:9182112-Amoxicillin, pubmed-meshheading:9182112-Amoxicillin-Potassium Clavulanate Combination, pubmed-meshheading:9182112-Cefuroxime, pubmed-meshheading:9182112-Cephalosporins, pubmed-meshheading:9182112-Child, pubmed-meshheading:9182112-Clavulanic Acids, pubmed-meshheading:9182112-Community-Acquired Infections, pubmed-meshheading:9182112-Double-Blind Method, pubmed-meshheading:9182112-Drug Administration Schedule, pubmed-meshheading:9182112-Drug Therapy, Combination, pubmed-meshheading:9182112-Female, pubmed-meshheading:9182112-Humans, pubmed-meshheading:9182112-Male, pubmed-meshheading:9182112-Middle Aged, pubmed-meshheading:9182112-Pneumonia, Bacterial, pubmed-meshheading:9182112-Prodrugs, pubmed-meshheading:9182112-Prospective Studies, pubmed-meshheading:9182112-Treatment Outcome
pubmed:year
1996
pubmed:articleTitle
Comparison of oral cefuroxime axetil and oral amoxycillin/clavulanate in the treatment of community-acquired pneumonia.
pubmed:affiliation
Hospital General de Mexico, Mexico City.
pubmed:publicationType
Journal Article, Clinical Trial, Comparative Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Multicenter Study